Guidance
← Отчётные звонки
01
02
03
04 05 06
Тон
AI
Капзатраты
A1 A2
TMO
FY2025 Q3
Повышен
Отчётный звонок Thermo Fisher Scientific Inc
Вывод Buzzberg
Guidance raised for full-year 2025 revenue and EPS.
Thermo Fisher delivered a strong Q3 with 5% revenue growth and raised full-year guidance. Management highlighted strategic collaborations with OpenAI and AstraZeneca, completed acquisitions of Solventum's filtration business and a Sanofi fill-finish site, and noted increasing pharma reshoring activity. Academic/government end market remained weak but showed modest improvement. Q3 revenue $11.12B (+5% y/y), adjusted EPS $5.79 (+10%), operating margin 23.3% (+100 bps).
Вывод Buzzberg Guidance raised for full-year 2025 revenue and EPS. Thermo Fisher delivered a strong Q3 with 5% revenue growth and raised full-year guidance. Management highlighted strategic collaborations with OpenAI and AstraZeneca, completed acquisitions of Solventum's filtration business and a Sanofi fill-finish site, and noted increasing pharma reshoring activity. Academic/government end market remained weak but showed modest improvement. Q3 revenue $11.12B (+5% y/y), adjusted EPS $5.79 (+10%), operating margin 23.3% (+100 bps). Читать полный анализСвернуть анализ
Thermo Fisher delivered a strong Q3 with 5% revenue growth and raised full-year guidance. Management highlighted strategic collaborations with OpenAI and AstraZeneca, completed acquisitions of Solventum's filtration business and a Sanofi fill-finish site, and noted increasing pharma reshoring activity. Academic/government end market remained weak but showed modest improvement. Q3 revenue $11.12B (+5% y/y), adjusted EPS $5.79 (+10%), operating margin 23.3% (+100 bps).
- Full-year revenue guidance raised to $44.1-44.5B, EPS to $22.60-22.86.
- Collaboration with OpenAI to embed AI into clinical research and internal operations.
- Acquired Solventum filtration business (~$750M annual revenue) and Sanofi sterile fill-finish site.
Выручка$11.122BФакт
EPS$5.79Факт
Валовая маржа41.83%Факт
Операционная маржа17.47%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
AI
OpenAI partnership to embed AI in products and internal ops.
Demand
Clinical research business returns to low single-digit growth.
Показать ещё 3 тезиса
Demand
Pharma reshoring conversations with customers are active.
Macro
Biotech funding and deal activity improving, aiding ecosystem.
Margins
Q3 EPS beat driven by strong operational performance, partly offset by acquisitions.
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $11.122B | Факт |
| EPS | $5.79 | Факт |
| Валовая маржа | 41.83% | Факт |
| Операционная маржа | 17.47% | Факт |
| Свободный денежный поток | $1.835B | Факт |
| Капзатраты | $0.404B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| Капзатраты | FY2025 | $1.4B–$1.7B | $1.55B | Подтверждён |
| EPS | FY2025 | $22.60–$22.86 | $22.73 | Повышен |
| Свободный денежный поток | FY2025 | $7B | $7B | Подтверждён |
| Операционная маржа | FY2025 | 22.7%–22.8% | 22.75% | Повышен |
| Выручка | FY2025 | $44.1B–$44.5B | $44.3B | Повышен |
AI, капзатраты и спрос
Оценка менеджмента
Upbeat
Management expressed confidence in execution, raised guidance for the full year, and highlighted strong demand from pharma and biotech customers.
Оценка AI от менеджмента
Management discussed embedding OpenAI technology into products and services to improve clinical trial cycle times, and deploying ChatGPT Enterprise internally to drive productivity. They also mentioned co-creating capabilities leveraging data repository to add value for customers.
Инвестиции и мощности
Management raised full-year 2025 capex guidance to $1.4-$1.7 billion net capital expenditures. They also highlighted investments in a new sterile fill-finish site in the U.S. and a manufacturing center of excellence in Mebane, North Carolina, to support reshoring and U.S. supply chain resilience.
все упомянутые компании ниже: 8
Компаниис момента звонка
Партнёры
OPENAI
Партнёры
Mark Masper
Thermo Fisher is tightly integrating OpenAI's AI into its products and internal operations, which could accelerate drug development and enhance competitive positioning.
Доказательства
“We are embedding OpenAI advanced technology into critical areas of our business, including product development, service delivery, customer engagement, and operations.”
Партнёры
Mark Masper
Co-location of Thermo Fisher scientists with AstraZeneca could deepen R&D collaboration and drive instrument and consumables sales.
Доказательства
“The recently announced strategic partnership with AstraZeneca BioVenture Hub in Gothenburg, Sweden.”
Цепочка поставок
Цепочка поставок
Mark Masper
Thermo Fisher adds bioprocessing and industrial filtration capabilities, expanding its addressable market and customer base.
Доказательства
“We completed our acquisition of our filtration and separation business from Solventum, which is now part of our life sciences solution segment.”
Цепочка поставок
Mark Masper
Thermo Fisher gains a new U.S. sterile fill-finish node with built-in Sanofi volume, supporting reshoring demand.
Доказательства
“We closed our acquisition of the Ridgefield, New Jersey, sterile fill finish site from Sanofi, expanding our U.S. drug product manufacturing.”
Цепочка поставок
Mark Masper
Thermo Fisher's new Mebane, NC facility can produce 40 million pipette tips per week, directly addressing U.S. lab consumable supply chain resilience. — Increases domestic capacity and may reduce reliance on Asian suppliers, pressuring competitors in the lab consumables space.
Доказательства
“A high-volume, low-cost facility, this site was developed with support from the U.S. government and is capable of producing at least 40 million laboratory pipette tips per week.”
Цепочка поставок
Mark Masper
Pharma customers are actively reshoring manufacturing to the U.S., creating near-term construction/equipment demand and long-term recurring consumables growth for Thermo Fisher. — Steers large pharma spending toward Thermo Fisher's U.S. sites and could shift market share from European CDMOs.
Доказательства
“We are actively engaged in helping those customers think about new sites, how to best equip them, and support our customers in that effort.”
Внешние сигналы
Альфа цепочки поставок · 2с момента звонка
Thermo Fisher's new Mebane, NC facility can produce 40 million pipette tips per week, directly addressing U.S. lab consumable supply chain resilience.
Pharma customers are actively reshoring manufacturing to the U.S., creating near-term construction/equipment demand and long-term recurring consumables growth for Thermo Fisher.
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 8. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.